No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GMED240517C60000
- 2.05
- 0.000.00%
15min DelayTrading May 8 15:53 ET
0.00High0.00Low
0.00Open2.05Pre Close0 Volume93 Open Interest60.00Strike Price0.00Turnover23.33%IV0.49%PremiumMay 17, 2024Expiry Date2.07Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.8629Delta0.0988Gamma26.13Leverage Ratio-0.0359Theta0.0120Rho22.55Eff Leverage0.0209Vega
Intraday
- 5D
- 1D
News
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 37.35% Barclays $83 → $85 Maintains Overweight 05/08/2024 1.8% BTIG $60 → $63 Maintains Buy 05/
Express News | Globus Medical Inc : Barclays Raises Target Price to $85 From $83
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)
Globus Medical's Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
Top Gap Ups and Downs on Wednesday: UBER, BUD, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Comments
The company's CEO, Dan Scavilla, expressed confidence in Pfeil's ability to drive operational efficiency and deliver profitable growth, especially in light of the ongoing integration following their merger with NuVasive.
Press Release: Globus Medical Promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerGlobus Medical's superior earnings outlook is contributing to its high P/E, which shareholders are currently comfortable with, expecting not to face a threat to future earnings. The confidence in the future earnings performance supports the current share price.
Globus Medical's persisting issues impact its valuation and a drop in EPS may spark shareholder worry. The long-term share performance is lackluster, unsettling even potential contrarian investors seeking a turnaround.
Read more